A phase II, multicenter, single-arm study of MPDL3280a in patients with PD-L1-positive locally advanced or metastatic Non-Small Cell Lung Cancer

The primary efficacy objective for this study is to evaluate the efficacy of MPDL3280A in patients with PD-L1?positive locally advanced or metastatic NSCLC, as measured by investigator-assessed ORR according to modified RECIST